Trial Profile

Myeloma X Relapse (Intensive)-a comparison of high versus low-dose alkylating agent consolidation regimens for relapsed myeloma.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melphalan (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin
Indications Multiple myeloma
Focus Registrational; Therapeutic Use

Most Recent Events

10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
12 Aug 2013 Biomarkers information updated
11 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com